



ENDO 2025

July 12-15, 2024; San Francisco, CA; Highlights – Draft

---

**Welcome to our resource hub for the Annual Meeting of the Endocrine Society (ENDO) 2025!** This is a one-stop-shop for all your ENDO 2025 needs. We will be updating the resource hub daily during the conference, so check back in for the latest on this fantastic meeting.

## Table of Contents

[Useful Conference Links](#)

[Day-of Conference Reports](#)

[Diabetes Therapy Highlights](#)

[Diabetes Technology Highlights](#)

[Big Picture Highlights](#)

[Previous ENDO Coverage on CCKB](#)

## Useful Conference Links

1. [Conference Website](#)
2. [Conference Registration](#)
3. [Day-by-Day Conference Preview](#)
4. [Conference Program](#)

## Day-of Conference Reports

1. [ENDO 2025: T1D Fellows Day](#)
2. [ENDO 2025 Day #1 Highlights](#)
3. [ENDO 2025 Day #2 Highlights](#)
4. [ENDO 2025 Day #3 Highlights](#)
5. [ENDO 2025 Day #4 Highlights](#)

## Diabetes Therapy Highlights

1. [Dr. Anders Carlson on the next frontier](#) in cardio-renal-metabolic care for type 1 diabetes
2. [Updates on insulin treatment](#), from pediatrics to adults to innovation
3. [Dr. Desmond Schatz on current and future immunotherapies for T1D](#)
4. [Dr. Melanie Haines reviews muscle preservation strategies](#) during GLP-1 RA-induced weight loss in obesity
5. [Dr. Christian Roth on a novel MC4R/GLP-1 receptor co-agonist](#) peptide and its promise for glycemic and weight reduction
6. [Real-world perspectives on the clinical use of verapamil](#) in T1D from Dr. Tugce Akcan
7. [Hypercortisolism in difficult-to-manage T2D](#): Experts review SEISMIC, CATALYST trials, and real-world evidence of Korlym
8. [The liver alpha cell axis](#): Glucagon action in diabetes, obesity, and MASLD

9. [Novel obesity therapeutics show promise](#): Amplifier’s dual AMPK and mitochondrial activator ATX-304, Juvena’s JUV-112, and Syntis Bio’s PERMEATE platform
10. [Beyond lifestyle: A review of the advances in the pharmacological management](#) of pediatric obesity
11. [SGLT-2 inhibitors in practice](#): Minimizing risk and maximizing benefit for people with T2D
12. [Tips for endocrinologists](#): MASLD and its clinical considerations in an endocrinology clinic
13. [Incretins as “silver bullets”](#): Prof. Jens Juul Holst reviews incretin physiology and clinical benefits
14. [Post-plenary perspectives](#): Redefining obesity, individualizing treatment, and GLP-1 RAs in practice
15. [Tirzepatide confers greater weight loss](#) and cardiometabolic gains in women
16. [Obesity pharmacotherapies](#): Where we’ve been, where we are now, and where we’re going

## Diabetes Technology Highlights

1. [A deep dive into CGM optimization](#) in clinical practice for AID and MDI
2. [Exercise management in T1D](#): Dr. Dessi Zaharieva shares tips and resources
3. [Year-in-review of diabetes technology](#): Global data, early CGM/AID, ketone monitoring, and equity in access
4. [Dr. Rayhan Lal calls for equitable access to advanced diabetes technology](#), offers practical strategies for clinicians managing T1D using AID, and reviews open-source innovation
5. [AID systems improve glycemic management without increasing hypoglycemia](#) in older adults with T1D versus sensor-augmented pump therapy
6. [Interpreting A1c and CGM data](#): Their strengths, pitfalls, and clinical pearls on complementary use

## Big Picture Highlights

1. [How to offer pediatric obesity and T1D](#) management without stigma
2. [Seizing the serpent](#): Spotting, sizing up, and subduing insulin resistance in T1D
3. [Dr. Alyson Myers discusses the impact of implicit bias](#) and differential access on diabetes care
4. [JCEM publishes guidelines](#) for managing pre-existing diabetes during pregnancy
5. [Dr. Lowell Schmeltz discusses T1D screening](#), monitoring, and clinical considerations with Tziield
6. [The intersection of food insecurity, obesity, and inequity](#): A geospatial analysis of food deserts in Texas
7. [Bonus: Bustling Exhibit Hall opens at ENDO 2025](#)
8. [Dr. Fatima Cody Stanford spotlights 2025 Scientific Report](#) on nutrition and *Lancet Commission* on obesity definition
9. [Understanding the pathogenesis of T1D](#): An Endocrine Society scientific statement
10. [Triglyceride-glucose index as a predictor of CKD](#) progression in adults with T2D
11. [The year in obesity](#): An overview of where we are and where we are going
12. [Weight stigma in healthcare](#): Impact, consequences, and a call to action
13. [Dr. Jennifer Kelley reviews current screening guidelines](#) and management of adolescent hypercholesterolemia
14. [Quality improvement for inpatient diabetes care](#): Seven steps to successful implementation
15. [Evolving obesity care](#): A comparative look at surgery vs. medications
16. [Obesity management across the lifespan](#): Reproductive, pediatric, and geriatric considerations
17. [Dr. Ellen Seely emphasizes gestational diabetes as a critical predictor](#) of T2D and cardiovascular disease risk

18. [Dr. Lisa Beutler describes biology behind obesity](#), from incretins to AgRP neuron activity
19. [Unique challenges of youth-onset T2D](#) and the need for earlier, targeted intervention
20. [Genetic architecture of youth-onset T2D](#) and insights from the ProDiGY consortium
21. [Metabolic imprinting](#): The transgenerational impact of gestational diabetes on youth-onset T2D

### **Previous ENDO Coverage on CCKB**

1. [ENDO 2024 Resource Hub](#)
2. [ENDO 2023 Resource Hub](#)
3. [ENDO 2022 Resource Hub](#)
4. [ENDO 2021 Resource Hub](#)
5. [ENDO 2020](#)
6. [ENDO 2019 Full Report](#)